603087 Stock Overview
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Gan & Lee Pharmaceuticals. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥48.00 |
52 Week High | CN¥62.90 |
52 Week Low | CN¥32.10 |
Beta | 1.61 |
1 Month Change | 19.31% |
3 Month Change | 18.55% |
1 Year Change | 34.60% |
3 Year Change | -64.67% |
5 Year Change | n/a |
Change since IPO | -26.30% |
Recent News & Updates
Shareholder Returns
603087 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 11.3% | -1.6% | -0.4% |
1Y | 34.6% | -24.8% | -14.4% |
Return vs Industry: 603087 exceeded the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 603087 exceeded the CN Market which returned -14.4% over the past year.
Price Volatility
603087 volatility | |
---|---|
603087 Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.8% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603087's share price has been volatile over the past 3 months.
Volatility Over Time: 603087's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 4,057 | Kai Du | www.ganlee.com |
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices.
Gan & Lee Pharmaceuticals. Fundamentals Summary
603087 fundamental statistics | |
---|---|
Market cap | CN¥28.32b |
Earnings (TTM) | CN¥386.85m |
Revenue (TTM) | CN¥2.61b |
73.2x
P/E Ratio10.8x
P/S RatioIs 603087 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603087 income statement (TTM) | |
---|---|
Revenue | CN¥2.61b |
Cost of Revenue | CN¥698.84m |
Gross Profit | CN¥1.91b |
Other Expenses | CN¥1.52b |
Earnings | CN¥386.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.66 |
Gross Margin | 73.23% |
Net Profit Margin | 14.82% |
Debt/Equity Ratio | 0.02% |
How did 603087 perform over the long term?
See historical performance and comparison